Sentinel Diagnostics (Sentinel CH S.p.A.) is pleased to announce that on June 18th has signed an agreement with BE Biotech Srl to acquire the rights to manufacture and distribute the G6PDH Products.
The two companies has defined a transition plan to ensure the continuity and quality of the service offered by BE Biotech Srl and to keep the same customer experience on G6PDH products. All the products will maintain the technical specifications and quality supplied by BE Biotech Srl as well as there will be no changes in the products’ Reference Number.
For additional details about the agreement between Sentinel CH S.p.A. and BE Biotech srl, please send an email to marketing@sentinel.it
